<DOC>
	<DOCNO>NCT01144364</DOCNO>
	<brief_summary>This study evaluate efficacy safety brief induction therapy chemotherapeutic regimen contain MabThera , follow either maintenance therapy MabThera therapy . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Elderly Patients With Untreated Follicular Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient 6075 year age ; Bcell follicular NHL ; previous treatment ; active disease , rapid progression . cancer within 3 year study , except carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer , ductal carcinoma situ breast treat lumpectomy ; longterm use ( &gt; 1 month ) systemic corticosteroid ; central nervous system involvement ; history significant cardiovascular disease ; positive test result HIV , hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>